Statement: Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events.
Primary_evidence: Adverse Events 1:   Total: 10/50 (20.00%)   Anaemia 0/50 (0.00%)   Febrile neutropenia 0/50 (0.00%)   Neutropenia 0/50 (0.00%)   Thrombocytopenia 0/50 (0.00%)   Diastolic dysfunction 0/50 (0.00%)   Tachycardia 0/50 (0.00%)   Intestinal obstruction 0/50 (0.00%)   Nausea 1/50 (2.00%)   Oesophageal spasm 0/50 (0.00%)   Oesophagitis 0/50 (0.00%)   Retching 0/50 (0.00%) Adverse Events 2:   Total: 11/48 (22.92%)   Anaemia 4/48 (8.33%)   Febrile neutropenia 0/48 (0.00%)   Neutropenia 2/48 (4.17%)   Thrombocytopenia 2/48 (4.17%)   Diastolic dysfunction 1/48 (2.08%)   Tachycardia 1/48 (2.08%)   Intestinal obstruction 0/48 (0.00%)   Nausea 0/48 (0.00%)   Oesophageal spasm 1/48 (2.08%)   Oesophagitis 0/48 (0.00%)   Retching 1/48 (2.08%)